A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

AstraZeneca591 enrolled

Overview

This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.

Study Type

OBSERVATIONAL

Enrollment

591

Conditions

Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological diagnosed as adenocarcinoma type of non-small cell lung cancer * Have completed lung cancer operation * The tumour EGFR gene mutation status test was performed as regular medical practice Exclusion Criteria: * Patients who disagree to participate this study

Locations (13)

Research Site

Beijing, Beijing Municipality, China

Research Site

Chongqing, Chongqing Municipality, China

Research Site

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

type and prevalence of EGFR mutation

Time frame: up to 3 months

Secondary Outcomes

Operation type and adjuvant treatment type

Time frame: up to 3 months

Disease Free Survival rate

Time frame: up to 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.